3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
73
Lung Neoplasms
32
Breast Neoplasms
19
Head and Neck Neoplasms
16
Neoplasms
11
Glioblastoma
8
Adenocarcinoma of Lung
8
Squamous Cell Carcinoma of Head and Neck
7
Colorectal Neoplasms
7
Brain Neoplasms
7
Adenocarcinoma, Bronchiolo-Alveolar
7
Prostatic Neoplasms
6
Neoplasm Metastasis
6
Gliosarcoma
6
Rectal Neoplasms
5
Ovarian Neoplasms
5
Colonic Neoplasms
5
Esophageal Neoplasms
4
Central Nervous System Neoplasms
4
Carcinoma
4
Unspecified Adult Solid Tumor, Protocol Specific
3
Respiratory Tract Diseases
3
Fallopian Tube Neoplasms
3
Carcinoma, Renal Cell
3
Carcinoma, Ovarian Epithelial
3
Adenocarcinoma Of Esophagus
3
Adenocarcinoma
3
Urinary Bladder Neoplasms
2
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Interventions
osimertinib
1
Gefitinib
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
×
Gefitinib
×
Clear all
NCT02296125
2026-04-21
FLAURA
AstraZeneca
Phase 3
Completed
674 enrolled
21 charts
1 FDA